Ratings Hikal Limited

Equities

HIKAL

INE475B01022

Market Closed - Bombay S.E. Other stock markets 06:00:50 2024-05-21 am EDT			5-day change	1st Jan Change
293.6 ^INR	-1.59%		+4.63%	-3.28%

May. 09	Transcript : Hikal Limited, Q4 2024 Earnings Call, May 09, 2024
May. 09	Hikal Limited Recommends Finally Dividend for the Financial Year 2023-2024	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 53.37 times its estimated earnings per share for the ongoing year.
The company appears highly valued given the size of its balance sheet.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
HIKAL LIMITED	-3.28%	442M	C
ELI LILLY AND COMPANY	+37.81%	705B	C+
NOVO NORDISK A/S	+32.82%	583B	B
JOHNSON & JOHNSON	-3.54%	364B	C+
MERCK & CO., INC.	+20.37%	332B	B-
ABBVIE INC.	+5.34%	291B	C+
ASTRAZENECA PLC	+16.64%	238B	B+
ROCHE HOLDING AG	-4.13%	210B	A+
NOVARTIS AG	+10.63%	209B	B-
AMGEN INC.	+8.56%	169B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders